Diabetic Retinopathy – Epidemiology – Epidemiology – Diabetic Retinopathy – Mature Markets

Clarivate Epidemiology’s coverage of diabetic retinopathy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of diabetic retinopathy for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

Clarivate Epidemiology’s diabetic retinopathy forecast will answer the following questions:

  • Of all people diagnosed with diabetic retinopathy, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of diabetic retinopathy over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts eight diabetic retinopathy patient populations, as follows:

  • Total prevalent cases of diabetic retinopathy.
  • Total prevalent cases of nonproliferative diabetic retinopathy.
  • Total prevalent cases of proliferative diabetic retinopathy.
  • Total prevalent cases of nonproliferative diabetic retinopathy by severity.
  • Diagnosed prevalent cases of severe nonproliferative diabetic retinopathy.
  • Diagnosed prevalent cases of proliferative diabetic retinopathy.
  • Diagnosed drug-treated prevalent cases of severe nonproliferative diabetic retinopathy.
  • Diagnosed drug-treated prevalent cases of proliferative diabetic retinopathy.

Note: Coverage may vary by country.